A new fast-acting insulin option for treatment of diabetes in adults


eMediNexus    01 October 2017

A new faster acting within 2.5 minutes mealtime version of insulin aspart Fiasp Novo Nordisk for the treatment of type 1 and type 2 diabetes in adults by the US Food and Drug Administration FDA . It also contains niacinamide to increase speed of the initial insulin absorption. Available as a prefilled delivery device and in a vial Fiasp is to be administered at the beginning of a meal or within 20 min after starting a meal.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.